Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Merkel Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 4Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1

Interventions

Gemcitabine 2Cisplatin 2pembrolizumab 1enfortumab vedotin 1copanlisib 1avelumab 1LHRH, lysine(6)-doxorubicin 1Carboplatin 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ureteral Neoplasms × avelumab × Clear all
NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡